X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (961) 961
Book Chapter (10) 10
Dissertation (4) 4
Publication (4) 4
Conference Proceeding (3) 3
Book / eBook (1) 1
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aflibercept (904) 904
science & technology (567) 567
life sciences & biomedicine (564) 564
ophthalmology (465) 465
humans (437) 437
ranibizumab (394) 394
bevacizumab (322) 322
vascular endothelial growth factor (289) 289
female (250) 250
intravitreal injections (242) 242
male (241) 241
aged (210) 210
macular degeneration (206) 206
vascular endothelial growth factor a - antagonists & inhibitors (206) 206
genetic structures (190) 190
recombinant fusion proteins - administration & dosage (180) 180
age-related macular degeneration (176) 176
receptors, vascular endothelial growth factor - administration & dosage (175) 175
eye diseases (168) 168
recombinant fusion proteins - therapeutic use (161) 161
angiogenesis inhibitors - therapeutic use (154) 154
treatment outcome (151) 151
receptors, vascular endothelial growth factor - therapeutic use (145) 145
middle aged (144) 144
visual acuity (142) 142
aged, 80 and over (123) 123
diabetic retinopathy (123) 123
oncology (121) 121
care and treatment (120) 120
angiogenesis inhibitors - administration & dosage (118) 118
tomography, optical coherence (116) 116
sense organs (113) 113
medicine & public health (112) 112
wet macular degeneration - drug therapy (110) 110
retrospective studies (107) 107
anti-vegf (105) 105
pharmacology & pharmacy (105) 105
retina (105) 105
follow-up studies (100) 100
patients (97) 97
age (91) 91
angiogenesis (89) 89
drug therapy (83) 83
colorectal cancer (81) 81
diabetic macular edema (80) 80
edema (80) 80
vegf (78) 78
animals (77) 77
endothelial growth factors (75) 75
fluorescein angiography (75) 75
physiological aspects (75) 75
analysis (74) 74
cancer (73) 73
choroidal neovascularization (73) 73
recombinant fusion proteins - adverse effects (72) 72
macular degeneration - drug therapy (62) 62
ranibizumab - administration & dosage (62) 62
wet macular degeneration - diagnosis (62) 62
acuity (61) 61
neovascular age-related macular degeneration (61) 61
prospective studies (61) 61
intravitreal injection (60) 60
research (60) 60
review (60) 60
diabetes (58) 58
receptors, vascular endothelial growth factor - antagonists & inhibitors (56) 56
neovascularization (54) 54
studies (54) 54
time factors (54) 54
colorectal neoplasms - drug therapy (53) 53
eye (53) 53
macular edema - drug therapy (53) 53
angiogenesis inhibitors - adverse effects (52) 52
chemotherapy (52) 52
choroidal neovascularization - drug therapy (52) 52
clinical trials (52) 52
macular edema (52) 52
original research (52) 52
fundus oculi (51) 51
polypoidal choroidal vasculopathy (51) 51
angiogenesis inhibitors - pharmacology (50) 50
recombinant fusion proteins - pharmacology (50) 50
visual acuity - physiology (50) 50
adult (49) 49
clinical ophthalmology (47) 47
metastatic colorectal cancer (46) 46
medical imaging (45) 45
ziv-aflibercept (45) 45
anti-vascular endothelial growth factor (42) 42
antibodies, monoclonal, humanized - therapeutic use (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
dose-response relationship, drug (42) 42
optical coherence tomography (42) 42
medical research (41) 41
angiogenesis inhibitors (40) 40
metastasis (40) 40
ranibizumab - therapeutic use (40) 40
receptors, vascular endothelial growth factor (40) 40
original (39) 39
regorafenib (39) 39
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (933) 933
Russian (26) 26
Spanish (21) 21
French (11) 11
German (11) 11
Czech (4) 4
Italian (4) 4
Chinese (2) 2
Japanese (2) 2
Portuguese (2) 2
Turkish (2) 2
Korean (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Archivos de la Sociedad Española de Oftalmología, ISSN 0365-6691, 07/2017, Volume 92, Issue 7, pp. 330 - 333
Clinical case A 14 year-old boy with Coats’ disease in his right eye, presented with a visual acuity (VA) of 0.1, micro-aneurysms, exudates, a macular oedema... 
Argon laser | Aflibercept | Ranibizumab | Coats’ disease
Journal Article
Archivos de la Sociedad Española de Oftalmología, ISSN 0365-6691, 03/2015, Volume 90, Issue 1, pp. 6 - 10
Aflibercept is a fusion protein whose chemical structure combines the constant fraction of any IgG with a variable fraction constructed with fundamental parts... 
Anti-VEFG | Pharmacology | Aflibercept | Pharmacokinetics
Journal Article
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 06/2015, Volume 122, Issue 6, pp. 1212 - 1219
Journal Article
International journal of ophthalmology, ISSN 2222-3959, 2016, Volume 9, Issue 11, pp. 1541 - 1548
AIM: To evaluate whether trapping vascular endothelial growth factor-A(VEGF-A) would suppress angiogenesis and inflammation in dry eye corneas in a murine... 
Inflammation | Dexamethasone | Neovascularization | Aflibercept | Dry eye | Life Sciences & Biomedicine | Ophthalmology | Science & Technology | dexamethasone | dry eye; aflibercept; neovascularization; inflammation; dexamethasone | dry eye | aflibercept | inflammation | neovascularization
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 01/2014, Volume 50, Issue 2, pp. 320 - 331
Abstract Purpose The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan... 
Hematology, Oncology and Palliative Medicine | Subgroup analysis | VEGF Trap | Aflibercept | Metastatic colorectal cancer | Performance status | Bevacizumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Leucovorin - administration & dosage | Prospective Studies | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatigue - chemically induced | Diarrhea - chemically induced | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Neutropenia - chemically induced | Recombinant Fusion Proteins - administration & dosage | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Receptors, Vascular Endothelial Growth Factor - adverse effects | Antimitotic agents | Care and treatment | Analysis | Colorectal cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents
Journal Article
Journal Article